The NK Cell Therapy Market is segmented by product type, with cellular products holding the largest share. This segment encompasses the live NK cell therapies that are administered to patients, including autologous and allogeneic NK cells, as well as engineered CAR-NK cells. The dominance of cellular products reflects the core therapeutic approach of NK cell therapy—using the cells themselves to target and eliminate diseased cells. Advances in manufacturing, including the use of iPSC-derived NK cells and optimized expansion protocols, are making these products more scalable and accessible.

While cellular products lead, therapeutic agents and reagents are the fastest-growing segments, driving innovation across the field. Therapeutic agents include cytokines, antibodies, and other molecules that modulate NK cell activity. These agents are often used in combination with NK cell therapies to enhance their potency, persistence, and homing to tumors. For example, IL-15 is a critical cytokine for NK cell survival and proliferation, and IL-15 superagonists are being developed as adjunctive therapies to boost NK cell function. Monoclonal antibodies that block inhibitory receptors on NK cells (such as NKG2A) or activate activating receptors (such as NKG2D) are also being explored as combination partners.

Reagents are essential components for the research, development, and manufacturing of NK cell therapies. This includes cytokines, growth factors, cell culture media, and transfection reagents used in the expansion and engineering of NK cells. The increasing complexity of NK cell manufacturing, including the use of gene editing and CAR engineering, is driving demand for high-quality, specialized reagents. The development of closed, automated manufacturing platforms is also creating new opportunities for reagent suppliers.

The growth of the therapeutic agents and reagents segments is closely tied to the overall expansion of the NK cell therapy pipeline. As more companies enter the field and advance products into clinical trials, the demand for these enabling technologies is expected to rise. Strategic partnerships between cellular therapy developers and reagent suppliers are becoming increasingly common, facilitating the development of optimized manufacturing processes. In April 2025, MaxCyte announced a contract win with AbbVie to provide its Flow Electroporation platform for manufacturing NK cell therapies, exemplifying this trend.

The interplay between cellular products, therapeutic agents, and reagents highlights the complexity of the NK cell therapy ecosystem. The success of cellular products depends on the availability of high-quality reagents and the development of effective combination strategies. As the market matures, the convergence of these segments will be critical to achieving the full potential of NK cell therapies.